Tamin

Quick links to important sections

Tamin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tamin

Quick Facts

Property Description
Active Ingredients Famotidine and Paracetamol (Acetaminophen)
Form Oral Tablet
Pharmacological Class H2-receptor antagonist and Analgesic/Antipyretic
General Purpose Symptom relief and gastric support
Origin Synthetic

What is Tamin and Its Unique Composition?

Tamin is defined as a fixed-dose combination product supplied as an oral solid dosage form (a tablet), containing two distinct synthetic active pharmaceutical ingredients: Famotidine and Paracetamol (Acetaminophen). This formulation is clinically recognized for integrating two essential therapeutic actions into one tablet. The oral route of administration ensures that both components are available systemically after ingestion. Tamin, as a specific brand formulation, is positioned to address the needs of adult patients seeking simultaneous relief from general discomfort and acid-related issues.


What Pharmacological Class Does Tamin Belong To?

Tamin holds a dual pharmacological identity, belonging to the H2-receptor antagonist and the Analgesic/Antipyretic classes. Famotidine is classified as an H2-receptor antagonist or H2 blocker, acting on receptors in the stomach lining. Paracetamol is classified as a non-opioid analgesic and antipyretic, widely established for its reliable relief of pain and fever. This dual-class composition is a core differentiating factor for Tamin, setting it apart from single-entity preparations. The formulation is intended to provide a comprehensive response where acute pain symptoms coincide with potential or existing gastric discomfort.


What is the General Therapeutic Purpose of Combining These Ingredients?

The general therapeutic purpose of Tamin is to achieve symptom relief, such as easing discomfort and reducing fever, while concurrently providing support against gastric discomfort or irritation. Pharmacological studies confirm that the Famotidine component ensures the inhibition of gastric acid secretion, a key function of H2-receptor antagonists. This mechanism helps decrease the amount of acid made in the stomach, which can provide relief from related symptoms. This integrated approach allows the Tamin oral tablet to address primary symptomatic relief alongside a common contributing factor, namely stomach acidity.

Regulatory References

  1. MedlinePlus Famotidine Drug Information
  2. Famotidine StatPearls - NCBI Bookshelf

What side effects are possible with Tamin?

Possible Side Effects and Safety Information

The safety profile of Tamin is based on the officially documented adverse reactions associated with its two components, Famotidine and Paracetamol (Acetaminophen), as classified by government regulatory agencies.


Adverse Reaction Categories

Side effects are classified by frequency and grouped into System-Organ Classes (SOC) based on the official label. Common reactions listed include Headache, Dizziness, Nausea, Constipation, and Diarrhea. Less frequently documented reactions, often classified as Uncommon, involve Rash, Pruritus, Fatigue, and Taste disorder. These effects are distributed across systems including Gastrointestinal Disorders, Nervous System Disorders, and Skin and Subcutaneous Tissue Disorders.


Serious Adverse Reactions

Official documents highlight the potential for Serious Adverse Reactions (SARs), which are rare but clinically important. These include Acute Liver Failure associated with the Paracetamol component, particularly when maximum daily dosing limits are exceeded from all sources. Both components are linked to rare Severe Skin Reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Other serious events include Hypersensitivity Reactions (e.g., Anaphylaxis) and, very rarely with Famotidine, Blood Dyscrasias (e.g., Pancytopenia).


Population-Specific Safety Constraints

Regulatory labeling specifies safety considerations for certain patient populations. Individuals with Severe Hepatic Impairment have restrictions on Paracetamol use due to the risk of hepatic injury. Patients with Renal Impairment are noted to have an increased risk of Central Nervous System (CNS) adverse reactions and potential Prolonged QT Interval when using the Famotidine component. Furthermore, safety information includes limitations such as the requirement to exclude Gastric Malignancy prior to initiating treatment with Famotidine.

Overdose and Emergency Response

The official regulatory profile for Tamin overdose is defined by the risks associated with both active components. Overdose is considered potentially severe and life-threatening due to the documented risk of hepatic necrosis and acute liver failure caused by the Paracetamol component. Early manifestations are often non-specific and may include Nausea, Vomiting, Abdominal Pain, and Pallor. However, severe outcomes like Jaundice, Encephalopathy, Metabolic acidosis, Acute renal failure, and Death can be delayed.

Overdose with the Famotidine component can present with Central Nervous System (CNS) adverse reactions, including Confusion, Hallucinations, Agitation, and Seizures, as well as cardiovascular effects like Hypotension and Tachycardia. These CNS effects are noted to have an increased risk in the elderly and patients with moderate to severe renal impairment.

Regulators mandate that individuals must seek immediate medical attention and contact a Poison Control Center immediately for any suspected overdose, even if no symptoms are apparent. Immediate treatment is essential. While N-acetylcysteine is the specific antidote for Paracetamol toxicity, the overall management involves symptomatic and supportive treatment and requires hospital monitoring of hepatic function and drug plasma concentrations.

Therapeutic Uses of Tamin

What Tamin Treats: Main Uses and Benefits

This medication is aligned with therapeutic contexts requiring dual symptomatic support. Tamin is commonly used to help manage symptoms related to physical discomfort and those linked to organ-specific functional stress. It is applied across domains where additional symptomatic support is needed, addressing conditions characterized by recurrent or episodic manifestations.

The combination is relevant for easing symptoms that interfere with daily functioning when patients experience both mild to moderate pain (such as headache or musculoskeletal aches) or fever alongside acid-related issues. It helps address symptom clusters including heartburn, acid indigestion, and sour stomach. This application is primarily seen in clinical settings where acute episodes or heightened discomfort require short-term symptomatic assistance.

“This medication supports patients during difficult episodes by easing the overall symptom burden, particularly when two types of discomfort coincide.”

It is applied in addressing symptom clusters that may become intense or disruptive, providing support for coincident symptoms to help improve general comfort during symptomatic periods.


Quick Fact: Support for Dual Discomfort

Property Description
Symptom Cluster Focus Pain/Fever and Acid-related distress
Typical Severity Mild to moderate discomfort
Use Context Acute or episodic symptomatic support
Patient Benefit Assists with maintaining functional stability

Regulatory References

  1. NIH MedlinePlus overview on Famotidine

Eligibility and Restrictions for Use

Who can and cannot use Tamin?

The official eligibility for Tamin, a combination of Famotidine and Paracetamol, is strictly governed by regulatory classifications for both active ingredients. The profile defines who can use the medicine and specifies populations where use is contraindicated or restricted.

Populations Excluded or Restricted

Tamin is contraindicated (must not be used) in patients with severe active liver disease or severe hepatic impairment. Use is also prohibited for individuals with a known hypersensitivity or allergic history to either Famotidine, Paracetamol, or any other H2-receptor antagonist. Patients experiencing symptoms of gastrointestinal hemorrhage, such as bloody stools or vomiting blood, are also excluded from use.

Eligibility by Age and Condition

Children under 12 years of age are not recommended to use this medicine, as use is not established for this group. For adults, specific physiological states require conditional use. Individuals with impaired renal function require a restricted, reduced dosage, as stated in the labeling. Use is not recommended for women who are pregnant or breastfeeding, and a decision must be made to discontinue the medicine or discontinue nursing. Caution is necessary for patients with comorbidities like chronic alcoholism or mild hepatic impairment, often requiring a reduction in the maximum allowed daily amount.

What should I know about interactions with other medicines?

Tamin Interactions with other medicines and products

Tamin (Thiamine/Vitamin B1) has a generally low risk for severe drug interactions. However, it can engage in moderate and minor interactions with several other medications and substances, primarily due to effects on drug concentration or the potential for additive adverse effects.

Key Interactions

Interacting Product Category Potential Effect Interaction Level
Macrolide Antibiotics (e.g., Azithromycin, Erythromycin) Moderate interaction, though clinical significance varies; careful monitoring is suggested. Moderate
Patiromer (a potassium binder) Patiromer may bind to Tamin in the gastrointestinal tract, potentially reducing its absorption and systemic availability. Moderate
Cisplatin (a chemotherapy agent) Cisplatin is known to inhibit the activity of thiamine, potentially leading to or exacerbating a thiamine deficiency. Moderate/Minor

Other Relevant Considerations

Chronic and excessive alcohol consumption is a well-documented cause of thiamine deficiency, as it impairs both the absorption and utilization of Tamin, necessitating repletion. Certain substances in coffee, tea, and raw fish contain thiamin antagonists that can potentially interfere with its metabolism. Additionally, certain medical conditions, such as renal impairment and malabsorption syndromes, may affect the body’s handling and status of this nutrient, which is a key interaction-related consideration for its safe and effective use.

Mechanism of Action

How Tamin Works

Tamin (Paracetamol/Acetaminophen) acts through targeted modulation of signaling pathways within the Central Nervous System (CNS). Its mechanism involves modulating key signaling pathways associated with central nociceptive signaling and thermoregulation.


Central Prostaglandin Synthesis Modulation

This domain covers the drug's effect on enzyme activity, specifically the inhibition of certain cyclooxygenase (COX) isoforms within the spinal cord and brain. This action suppresses the formation of prostaglandins in the CNS, which modifies molecular steps that influence subsequent downstream central signaling.


Hypothalamic Thermoregulatory Control

Tamin modulates the hypothalamic thermoregulatory center in the brain, the system responsible for setting the body's core temperature. By reducing the concentration of prostaglandin E2 ( PGE2) in this area, the drug effectively resets the elevated temperature set point. This supports a more regulated state within the targeted pathways, initiating efferent signals for heat dissipation, such as peripheral vasodilation and sweating.

Dosage and Administration Information

Tamin is an oral tablet designed as a fixed-dose combination, meaning it must be swallowed whole via the oral route of administration. Each tablet contains both an H2-receptor antagonist (Famotidine) and an analgesic/antipyretic (Paracetamol/Acetaminophen). The administration schedule synthesizes instructions for both components.

Dosing for the gastric support component is often structured for once or twice daily administration, sometimes scheduled before bedtime to help manage nocturnal acid secretion. Conversely, the Paracetamol component may be administered every 4 to 6 hours as needed for acute symptomatic relief. A strict minimum interval of 4 hours must be observed between subsequent doses. Tamin may be taken with or without food.

Guidelines establish a maximum total daily intake for the Paracetamol component, which must not exceed 4,000 mg from all sources in a 24-hour period. Therefore, co-administration with other Paracetamol-containing products is discouraged. Use is typically limited to a short-term course for symptomatic management, such as up to six weeks for the acid-reducing component.

Standard instructions also dictate dose adjustment rules for specific patient populations. The regimen requires modification in cases of renal impairment (due to the Famotidine component) or hepatic impairment (due to the Paracetamol component). These instructions ensure the medicine is used within standardized protocols.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tamin (Famotidine/Paracetamol)


The Research Basis for Dual Symptom Support

The research base for Tamin, a fixed-dose combination of Famotidine and Paracetamol, is structured around the documented physiological effects of each component individually, and studies exploring the rationale for combining them. Research examines this pairing in the context of symptom patterns where both outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states, such as stomach acid issues, are relevant. Trials and scientific literature have included bioequivalence studies to examine the delivery characteristics of both active ingredients from the fixed-dose tablet. The core evidence for the acid-reducing component is largely drawn from established monotherapy trials for Famotidine and analogous Fixed-Dose Combination (FDC) research where H2-antagonists were paired with other non-opioid pain relievers to assess gastric comfort outcomes.


Evidence for Acute Pain Relief and Concurrent Gastric Comfort

This segment summarizes the studies that assessed the fixed-dose combination's role in addressing acute mild to moderate pain while simultaneously including Famotidine, which is relevant in research exploring acid-related discomfort, including findings extrapolated from analogous H2RA/analgesic trials. Research has explored the combined use in adult populations experiencing conditions characterized by fluctuating or episodic manifestations of pain, such as headache or musculoskeletal aches, when the condition also involves outcomes linked to inflammatory or irritative states.

Findings describe patterns observed in these studies, where research explored whether the addition of the Famotidine component to an analgesic formulation was associated with differences in the rate of patient-reported outcomes describing perceived discomfort in the observed populations. Research highlights that the individual component actions have been extensively documented: Paracetamol was studied for outcomes related to physical discomfort and systemic imbalance, and Famotidine for decreasing stomach acid secretion. However, evidence remains limited regarding the specific comparative clinical performance of the Famotidine/Paracetamol FDC against taking Paracetamol alone for general acute pain relief, as this specific pairing has not been the subject of extensive, large-scale efficacy RCTs in published regulatory summaries.


Evidence for Fever Reduction and Associated Discomfort

Research related to fever and general discomfort is informed by the substantial existing evidence for the Paracetamol component itself. This area of research relies on extensive Meta-analyses and Systematic Reviews that have evaluated Paracetamol in isolation. These studies focused on outcomes related to systemic or functional imbalance, such as Change in Body Temperature and Patient-Reported Outcomes describing perceived discomfort during febrile episodes. Research reports how symptoms evolved in the observed populations, consistently documenting that Paracetamol was associated with changes measured in body temperature and pain indices. This evidence contributes to understanding symptom patterns across various conditions involving periods of heightened symptoms. Research provides insight into short-term changes.


Summary of Research Gaps and Unanswered Questions

The evidence landscape highlights certain areas where more research is needed to fully characterize the combination. The most significant research limitation is the comparative evidence is lacking from large-scale, robust RCTs that directly compare the outcomes related to physical discomfort of the Famotidine/Paracetamol FDC against Paracetamol monotherapy. The primary support for the combination’s study rationale comes from the well-documented effects of its individual ingredients and extrapolation from analogous FDC studies. Follow-up durations were limited in the FDC-specific studies, meaning there is limited information for long-term outcomes or the durability of response.

Key Studies & References

  1. Famotidine: MedlinePlus Drug Information (Mechanism of action and indications for acid reduction)
  2. Acetaminophen (Paracetamol) - StatPearls - NCBI Bookshelf (Evidence for antipyresis and analgesia)
  3. Famotidine - StatPearls - NCBI Bookshelf (Pharmacokinetics, indications, and special populations considerations)
  4. Histamine H2 receptor antagonists for decreasing gastrointestinal harms in adults using acetylsalicylic acid: systematic review (Evidence for H2RA in mitigating gastrointestinal harm from analgesics)
  5. Gastrointestinal injury associated with NSAID use: a case study and review (Contextual evidence for need of gastric comfort component in analgesic co-therapy)

Frequently Asked Questions (FAQ)

Common questions about Tamin (FAQ)

Q: How quickly can a person expect to notice the effects of Tamin?

A: The onset of action for the pain-relieving component (Acetaminophen) typically starts within 30 to 60 minutes. The acid-reducing component (Famotidine) generally begins working within one hour. Patients should review their expected timeline of relief with a healthcare provider.

Q: What kind of changes should I expect in my body after starting Tamin?

A: The medicine is designed to work in two main ways to support symptom management. One component is designed to reduce the amount of acid the stomach produces. The other component modulates pain and temperature regulation pathways in the central nervous system, which are the mechanisms intended to address discomfort and fever.

Q: Does Tamin help treat the underlying cause of the condition or just the symptoms?

A: The medicine is indicated for symptomatic relief of pain and fever. Additionally, the Famotidine component works to inhibit gastric acid secretion, which addresses a physiological factor (acid production) that can contribute to certain stomach symptoms. The overall purpose is defined as symptom management.

Q: Is Tamin available as an over-the-counter medicine?

A: The combination of Famotidine and Paracetamol may be available in both prescription (Rx) and certain dose-limited over-the-counter (OTC) formulations. The availability depends on the specific dosage strength and the regulatory guidelines in that country.

Q: For what general age range is Tamin typically prescribed?

A: Dosing and usage are established and specified for adult patients in the official regulatory labeling. Use is generally not recommended for children under 12 years of age, as safety and efficacy have not been established for this young population.

Q: Is Tamin classified as a controlled substance by regulatory bodies?

A: No. According to official government product status classifications, Tamin, which contains Famotidine and Paracetamol, is not classified as a controlled substance by drug enforcement agencies.

Q: How long does the active ingredient in Tamin generally remain detectable in the body?

A: Regulatory information includes data on how the drug is eliminated from the body. The elimination half-life of the Famotidine component is approximately 2.5 to 3.5 hours in adults with normal kidney function.

Q: What are the official recommendations if Tamin seems to not be working?

A: Official patient counseling advises checking with a healthcare provider if the condition does not improve or if symptoms worsen. This check is also recommended if symptoms persist beyond the short duration of use that is officially recommended.

Q: What signs or symptoms should prompt me to contact a healthcare professional after starting Tamin?

A: Official warnings advise seeking immediate medical attention if signs of a serious reaction occur. These can include unexplained symptoms like swelling of the face, tongue, or throat, difficulty breathing, or yellowing of the skin or eyes (jaundice). These are listed as important safety symptoms in the regulatory documents.

Q: Is it known if Tamin interacts with common pain relievers like ibuprofen or aspirin?

A: Regulatory documents advise patients to avoid using more than one medicine containing acetaminophen (Paracetamol) at the same time, as Tamin already contains this ingredient. To maintain safety, patients should consult a healthcare provider regarding the co-administration of Tamin with other pain relievers, including NSAIDs like ibuprofen or aspirin.

Q: Are there any foods or drinks that should be avoided while taking Tamin?

A: Official warnings caution against excessive or chronic consumption of alcohol while using Tamin. This is because alcohol can increase the potential for liver damage associated with the acetaminophen component. The medicine may generally be taken with or without food.

Q: Are there official warnings about combining Tamin with alcohol?

A: According to official product information for the acetaminophen component, severe liver damage may occur if a person consumes three or more alcoholic drinks per day. It is recommended that individuals with chronic alcoholism avoid the regular or excessive use of acetaminophen-containing products.

Q: Does Tamin interact with common vitamins or supplements?

A: Official guidance emphasizes that patients should inform their healthcare professional of all drugs, vitamins, and supplements they are taking. Certain components of Tamin, such as Famotidine, are noted to potentially interact with specific supplements like potassium binders.

Q: Does Tamin affect birth control medication?

A: Official prescribing information does not typically list an interaction between the active components, Famotidine or Paracetamol, and hormonal contraceptives. Patients should always review their full medication list with a healthcare professional.

Q: Are there specific medication types (e.g., blood pressure, depression) that are commonly known to interact with Tamin?

A: Known drug-drug interactions listed in regulatory documents include those with certain medication types, such as Macrolide Antibiotics and some chemotherapy agents (e.g., Cisplatin). Patients should have a healthcare professional review their full medication history.

Q: Does Tamin have any known interactions with grapefruit juice or other common food items?

A: Official prescribing information does not typically list an interaction with grapefruit juice for either the Famotidine or Paracetamol components. Patients should, however, always discuss diet and supplements with a healthcare provider.

Q: If a dose of Tamin is forgotten, what is the general guidance found in official prescribing information?

A: General patient guidance is usually to take the missed dose as soon as remembered if the next scheduled dose is not too close. Official guidance stresses that patients should not double the dose to make up for a missed one.

Q: Are there any specific laboratory tests required before or during Tamin treatment?

A: The regimen requires careful monitoring of kidney and liver function for patients with existing impairments, as a change in dosage may be necessary. These monitoring recommendations are detailed in the official safety and dosing guidelines for the individual components.

Q: Does Tamin have any known impact on the ability to drive or operate machinery?

A: Official documents list dizziness as a potential adverse reaction. Patients should be aware of how the medicine affects them personally before engaging in activities that require mental alertness and concentration, such as driving a vehicle or operating hazardous machinery.

Q: Is Tamin known to cause mood changes or affect mental health?

A: Rare psychiatric side effects are reported for the Famotidine component. These can include feelings of anxiety, agitation, depression, and confusion. These effects are generally uncommon and should be reported to a healthcare provider.

Q: Are the side effects of Tamin different for older adult populations?

A: Official documents note that older adults are observed to have an increased risk of Central Nervous System (CNS) adverse reactions. These effects, such as confusion or lethargy, are more likely to occur if the patient also has reduced kidney function.

Q: Can Tamin interfere with normal sleep patterns?

A: Rare psychiatric side effects reported for the Famotidine component include insomnia (difficulty sleeping) and agitation. Patients should speak with a healthcare provider if they experience new or worsening sleep disturbances.

Q: Has hair thinning or hair loss been reported as a side effect of Tamin?

A: Hair thinning or loss is not typically listed among the common or uncommon adverse reactions in the official regulatory documents for the active ingredients of Tamin.

Q: Do regulatory documents mention weight gain or weight changes associated with Tamin?

A: Official adverse reaction listings for the medicine's components do not typically include weight gain or loss as a common or serious side effect. Unexplained weight loss, however, is listed as a symptom that requires medical attention.

Q: Is it true that Tamin can cause changes in blood pressure readings?

A: Rare cardiovascular adverse effects, such as changes in heart rhythm, are noted in the labeling. However, significant changes to routine blood pressure readings are not typically listed as common or serious side effects in the official documents.

Q: What might happen if someone abruptly stops taking Tamin?

A: Since the medicine is generally intended for short-term use for symptomatic relief, official labeling does not usually describe specific withdrawal symptoms related to abrupt cessation.

Q: Does the efficacy of Tamin change over time with continued use?

A: The medicine is indicated for short-term use for symptomatic management. While research documentation may note a lack of long-term data for the specific combination, regulatory information does not detail a change in efficacy over extended periods of time.

How should Tamin be stored and disposed of?

How to Store and Dispose of Tamin

Storage Conditions: Tamin tablets must be stored at or below 25 C (77 F), corresponding to Controlled Room Temperature. It is mandatory to keep the medicine in its original container to protect it from light and moisture, and it must not be frozen. All Tamin tablets must be kept out of the sight and reach of children and pets.


Disposal Requirements: Do not use the medicine after the labeled expiry date. Unused or expired Tamin should not be disposed of via wastewater or household trash. The preferred method is to return the medicine to a pharmacy or an official drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Tamin found in:

A-Z Index: